Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alketa Hamzaj
Institution:
Ospedale San Donato
Observed institutions:
Azienda Ospedaliera di Perugia,
Azienda Usl 8 Arezzo,
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori,
Ospedale San Donato
OpenAlex ID:
A5113983937
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
2021
·
Toni K. Choueiri
, Thomas Powles
, et al.
·
New England Journal of Medicine
·
1,975
PDF
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
2020
·
Thomas Powles
, Michiel S van der Heijden
, et al.
·
The Lancet Oncology
·
536
PDF
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
2022
·
Robert J Motzer
, Thomas Powles
, et al.
·
The Lancet Oncology
·
361
PDF
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2022
·
Thomas Powles
, Piotr Tomczak
, et al.
·
The Lancet Oncology
·
346
PDF
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024
·
Robert J. Motzer
, Camillo Porta
, et al.
·
Journal of Clinical Oncology
·
235
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
2022
·
Arlene O Siefker-Radtke
, Andrea Necchi
, et al.
·
The Lancet Oncology
·
183
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
2015
·
S. Bracarda
, R. Iacovelli
, et al.
·
Annals of Oncology
·
108
PDF
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024
·
Brigida Anna Maiorano
, Massimo Di Maio
, et al.
·
JAMA Network Open
·
67
Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies
2015
·
Sergio Bracarda
, Amelia Altavilla
, et al.
·
Seminars in Oncology
·
57
Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
2022
·
Thomas Powles
, Toni K. Choueiri
, et al.
·
Journal of Clinical Oncology
·
31
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
2022
·
Francesca Vignani
, Rosa Tambaro
, et al.
·
European Urology
·
28
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
2018
·
Maria Giuseppa Vitale
, Sarah Scagliarini
, et al.
·
PLoS ONE
·
25
GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer
2013
·
Sergio Bracarda
, Michele Sisani
, et al.
·
Critical Reviews in Oncology/Hematology
·
21
Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
2022
·
Francesca Vignani
, Rosa Tambaro
, et al.
·
Journal of Clinical Oncology
·
13
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
2026
·
Robert J Motzer
, Ray McDermott
, et al.
·
The Lancet
·
12
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view
2014
·
Sergio Bracarda
, Michele Sisani
, et al.
·
Expert Review of Anticancer Therapy
·
11
Docetaxel Rechallenge in Metastatic Castration-Resistant Prostate Cancer: Any Place in the Modern Treatment Scenario? An Intention to Treat Evaluation
2015
·
Sergio Bracarda
, Claudia Caserta
, et al.
·
Future Oncology
·
9
Lung Cancer
2007
·
Lucio Crinò
, Jennifer Foglietta
, et al.
·
Journal of Thoracic Oncology
·
9
PDF
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication
2022
·
Sebastiano Buti
, Umberto Basso
, et al.
·
Journal of Immunotherapy
·
8
Sunitinib therapy in metastatic papillary thyroid cancer
2013
·
Stefania Gori
, Jennifer Foglietta
, et al.
·
Tumori Journal
·
8
Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.
2025
·
Thomas Powles
, Neal D. Shore
, et al.
·
Journal of Clinical Oncology
·
6
Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).
2017
·
Ugo De Giorgi
, Sarah Scagliarini
, et al.
·
Journal of Clinical Oncology
·
5
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.
2014
·
Sergio Bracarda
, Giuseppe Procopio
, et al.
·
Journal of Clinical Oncology
·
1
Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).
2013
·
Sergio Bracarda
, Alketa Hamzaj
, et al.
·
Journal of Clinical Oncology
·
1
Patterns of progression of patients with high-volume metastatic castration-sensitive prostate cancer treated with early docetaxel chemotherapy: The LONGITUDE observational study.
2022
·
Serena Macrini
, Annalisa Guida
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
26
Citation count:
4,056
H-index:
13
I10-index:
16
Year
Topic
Type